{"transactions":[{"id":445,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-02T20:13:09.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":1288,"price":9.7,"value":12493.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500."}],"balance_after":33226,"source":{"system":"sec-edgar","filing":"0000882796-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644246/000088279626000063/form4.xml","form_type":"4"}},{"id":738610,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2026-06-15T20:32:01.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":33540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":33540,"derivative":{"exercise_price":8.5,"exercise_date":"2027-06-11","expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":33540},"source":{"system":"sec-edgar","filing":"0000882796-26-000055","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000055/form4.xml","form_type":"4"}},{"id":738609,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-15T20:32:01.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":31938,"source":{"system":"sec-edgar","filing":"0000882796-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000055/form4.xml","form_type":"4"}},{"id":756039,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-02T20:16:22.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":1262,"price":8.91,"value":11244.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250."}],"balance_after":16644,"source":{"system":"sec-edgar","filing":"0000882796-26-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000033/form4.xml","form_type":"4"}},{"id":871222,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-03T21:36:58.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":528,"price":8.75,"value":4620.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625."}],"balance_after":15382,"source":{"system":"sec-edgar","filing":"0000882796-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000013/form4.xml","form_type":"4"}},{"id":930518,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2026-01-27T22:22:33.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":26684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option grant vests 1/36 per month over a 3-year period measured from the date of grant."}],"balance_after":26684,"derivative":{"exercise_price":6.79,"expiration_date":"2036-01-23","underlying":"Common Stock","underlying_shares":26684},"source":{"system":"sec-edgar","filing":"0000882796-26-000003","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000003/form4.xml","form_type":"4"}},{"id":930517,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-27T22:22:33.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":12272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the \"Director Compensation Policy\"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant."}],"balance_after":14854,"source":{"system":"sec-edgar","filing":"0000882796-26-000003","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000003/form4.xml","form_type":"4"}},{"id":930516,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-27T22:22:33.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":2582,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 4,377 shares of Astria Therapeutics, Inc. (\"Astria\") common stock in connection with a merger (the \"Merger\"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. (\"BioCryst\"). Pursuant to the Merger, each share of Astria common stock (subject to certain inapplicable exceptions) was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to applicable withholding taxes. On the last trading day before the effective date of the Merger, the closing price of Astria's common stock was $12.58 per share, and the closing price of BioCryst's common stock was $6.75 per share."}],"balance_after":2582,"source":{"system":"sec-edgar","filing":"0000882796-26-000003","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000003/form4.xml","form_type":"4"}},{"id":932209,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:33:25.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":761000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.41,"underlying":"Common Stock","underlying_shares":761000},"source":{"system":"sec-edgar","filing":"0000905148-26-000322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000322/form4.xml","form_type":"4"}},{"id":932208,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:33:25.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":195000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.51,"underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000905148-26-000322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000322/form4.xml","form_type":"4"}},{"id":932207,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-01-23T16:33:25.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4377,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-26-000322","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000322/form4.xml","form_type":"4"}},{"id":1192180,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-25T16:07:38.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":761000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 21, 2025 and is subject to vesting over a four-year period, with 25% of the 761,000 shares underlying the option upon grant vesting on the first anniversary of February 13, 2025 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":761000,"derivative":{"exercise_price":6.41,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":761000},"source":{"system":"sec-edgar","filing":"0001104659-25-027776","document":"tm2510055-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925027776/tm2510055-6_4seq1.xml","form_type":"4"}},{"id":1649097,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:06:04.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":534600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 534,600 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":534600,"derivative":{"exercise_price":15.26,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":534600},"source":{"system":"sec-edgar","filing":"0001104659-24-014617","document":"tm245876-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924014617/tm245876-5_4seq1.xml","form_type":"4"}},{"id":1865102,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T08:08:38.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the \"Company\") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the \"Stock Plan Amendment Proposal\"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 275,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":275000,"derivative":{"exercise_price":13.36,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001104659-23-068347","document":"tm2317752-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465923068347/tm2317752-13_4seq1.xml","form_type":"4"}},{"id":2354015,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T19:19:59.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 1, 2022, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This option was granted on March 1, 2022, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":195000,"derivative":{"exercise_price":6.51,"underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001104659-22-030181","document":"tm228319-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922030181/tm228319-3_4seq1.xml","form_type":"4"}},{"id":2686337,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T19:15:04.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":1400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the closing price of the common stock of Catabasis Pharmaceuticals, Inc. (the \"Company\") on April 1, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on April 1, 2021 subject to the approval by the stockholders of the Company of an increase in the number of shares of common stock available under the Company's Amended and Restated 2015 Stock Incentive Plan (\"Proposal No. 4\") at the Company's 2021 Annual Meeting of Stockholders (the \"Annual Meeting\"). Proposal No. 4 received the requisite approval at the Annual Meeting on June 2, 2021.  The option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":1400000,"derivative":{"exercise_price":2.87,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":1400000},"source":{"system":"sec-edgar","filing":"0001104659-21-075903","document":"tm2118270-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465921075903/tm2118270-4_4seq1.xml","form_type":"4"}},{"id":3270761,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-14T12:55:47.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 12, 2020, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":150000,"derivative":{"exercise_price":5.32,"expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001179110-20-001597","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911020001597/edgar.xml","form_type":"4"}},{"id":3653653,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-15T08:40:21.000Z","date":"2019-02-13","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 13, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":100000,"derivative":{"exercise_price":4.39,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-19-001940","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911019001940/edgar.xml","form_type":"4"}},{"id":3819548,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2018-09-11T16:12:11.000Z","date":"2018-09-07","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 7, 2018 and is subject to vesting over a two year period, with 50% of the shares vesting on the first anniversary of September 7, 2018 and the remainder vesting over the ensuing year at a rate of 4.1667% per month."}],"balance_after":230000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-09-06","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001179110-18-011280","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911018011280/edgar.xml","form_type":"4"}},{"id":4068492,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-09T16:01:49.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 8, 2018 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 8, 2018 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":230000,"derivative":{"exercise_price":1.28,"expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001179110-18-001881","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911018001881/edgar.xml","form_type":"4"}},{"id":4457149,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-10T16:04:42.000Z","date":"2017-02-09","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 9, 2017 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 9, 2017 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":200000,"derivative":{"exercise_price":1.24,"expiration_date":"2027-02-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001179110-17-002157","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911017002157/edgar.xml","form_type":"4"}},{"id":4604259,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-13T17:24:09.000Z","date":"2016-09-08","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security. The correct Exercise Price of the Derivative Security is $4.31 and was previously stated as $4.30."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the reminder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":45000,"derivative":{"exercise_price":4.31,"expiration_date":"2026-09-07","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001179110-16-029616","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911016029616/edgar.xml","form_type":"4/A","original_submission_date":"2016-09-12"}},{"id":4605758,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":410,"kind":"person","name":"Milne Jill C.","position":1,"cik":"0001644246","reported_name":"Milne Jill C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-12T16:14:31.000Z","date":"2016-09-08","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":45000,"derivative":{"exercise_price":4.3,"expiration_date":"2026-09-07","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001179110-16-029553","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911016029553/edgar.xml","form_type":"4"}}]}